

## Special Issue

# Feature Review Papers on Gastroesophageal Junction and Gastric Cancers

### Message from the Guest Editor

Cancer of the stomach and esophageal junction is one of the most frequent causes of cancer deaths around the world. This is due to a late diagnosis at the metastatic stage but also to resistance to classical chemotherapies. Peri-operative chemotherapy is the reference treatment for resectable gastric and esophageal cancers. In recent years, research has been marked by the classification of gastric cancer based on molecular subtypes, which opens the possibility of personalized therapy. Targeted therapies have recently emerged that focus on microsatellite instability, human epidermal growth factor receptor 2, programmed cell death ligand 1, and Epstein–Barr virus. Only a small proportion of patients with these cancers are eligible for targeted therapies. In addition, many new signaling pathways involved in gastric cancer have been identified in recent years, and the esogastric junction constitutes a potential lead for new target therapies. Research is particularly active in the field of immunotherapy and targeting of cancer stem cells.

### Guest Editor

Prof. Dr. Caroline Gronnier

Department of Digestive Surgery, Magellan Center, Bordeaux University Hospital, 33600 Pessac, France

### Deadline for manuscript submissions

closed (17 April 2023)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/112326](https://mdpi.com/si/112326)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)